Table S2 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

Key Points

• Refining traditional therapy for HR+/HER2- breast cancer offers improved outcomes in a real-world setting.
• This cohort study analyzed patients with early-stage breast cancer, providing insights for better treatment strategies.
• Utilizing subtyping to direct precision treatment may enhance therapeutic effectiveness compared to standard approaches.
• Such advancements call for future studies to validate the impact of subtyping on treatment success rates.